Kornimate/medical-research-clean huggingface dataset:
gw406381 in patients with peripheral nerve injury

Conditions: Hyperalgesia; Neurodynia; Pain; Trauma

Summary: the findings from preclinical animal models confirm the peripheral anti-inflammatory/analgesic activity of gw406381 and also suggest contribution of a central site of action to the anti-hyperalgesic efficacy that may not be shared by other cox-2 inhibitors. a central action is consistent with distribution of gw406381 into the cns in animals. furthermore, preliminary data from a positron emission tomography study in which 6 healthy male volunteers received a tracer dose of 11c labelled gw406381 indicate that gw406381 is rapidly absorbed into the central nervous system in man.


Eligibility criteria:
inclusion criteria: * baseline average daily pain score of greater than or equal to 4 (averaged over the 7 days prior to treatment visit 1), as reported on the 11 point pain intensity numerical rating scale. * subjects on medications for neuropathic pain or received nerve blocks for neuropathic pain. exclusion criteria: * known history of hypersensitivity or intolerance to acetaminophen, paracetamol, aspirin, cox-2 inhibitors or nsaids. * subject is unable to discontinue nsaids or cox-2 inhibitors (except aspirin as a cardioprotective; certain doses apply), topical lidocaine and topical capsaicin for the treatment of pain for the period prior to randomization and for the duration of the study. * subject is unable to refrain from sedative use during the study (benzodiazepines prescribed as hypnotic sleep agents allowed). * subject is unable to refrain from nerve blocks for 4 weeks prior to randomisation and during the study.

Keywords: gw406381 peripheral nerve injury patients allodynia hyperalgesia randomised placebo-controlled
coexistence hbsag/hbcac, clinical characterístics & outcomes

Conditions: Hepatitis B

Summary: hbv infection is a dynamic process with complex interactions between virus replication and the host's immune response. the appearance of anti-hbs after hbv infection generally indicates recovery and immunity to hbv1 infection. however, there are several published studies that describe the coexistence of the marker of chronic infection (hbsag +) and the marker of functional cure (hbsac +). there are contradictory studies on whether the coexistence of hbsag/hbsac implies a different clinical course.


Eligibility criteria:
inclusion criteria: * all those patients who have been seen in outpatient hepatology consultations and who present positive hbsag and hbsac serology simultaneously. exclusion criteria: * hepatitis c or hiv co-infection
transpulmonary pressure in right ventricle protection of ards

Conditions: Acute Respiratory Distress Syndrome; Acute Cor Pulmonale

Summary: to compare the effect between mechanical ventilation strategy guided by transpulmonary pressure and tranditional lung protective ventilation strategy in acute respiratory distress syndrome for right ventricle protection.


Eligibility criteria:
inclusion criteria: * duration of invasive mechanical ventilation less than 72 hours; * meet the diagnostic criteria of berlin definition for ards; * age older than 18 exclusion criteria: * esophageal surgery or damage; * cardiac surgery; * severe bronchopleural fistula; * serious arrhythmia; pneumothorax; * tricuspid stenosis; * heparin allergy; * chronic pulmonary heart disease
mental activity during (tms) therapy for depression

Conditions: Cognitive Impairment

Summary: the purpose of the study is to assess the effects of different types of mental activity performed while receiving transcranial magnetic stimulation (tms) for the treatment of major depressive disorder. our primary aim for this study is to assess the feasibility of combining tms and computer based cognitive exercise in patients with major depressive disorder who may also have some degree of cognitive dysfunction, and to formally measure changes in mood and cognition over the course of the study.

patients will receive tms treatment daily for 6 weeks as part of their standard care. they will complete clinical assessments and participate in cognitive retraining through completion of 15 hours of lumosity gaming cognitive exercises while simultaneously receiving active tms stimulation. those participants in the control group will complete 15 hours of computer gaming activity during the administration of active stimulation. computer games in the control group exercises are elected by the patient from a library of intellectually and motivationally engaging games drawn from several gaming software compilations that includes play 101 games and hoyle puzzle and board games.

Eligibility criteria:
inclusion criteria: * • subject has a diagnosis of depression * subject has been approved and scheduled to receive tms at augusta university * subject does not have a major neurocognitive impairment or an alcohol or substance abuse disorder, and can see images on a computer monitor. exclusion criteria: -

Keywords: depression, transcranial magnetic stimulation (tms)
a pharmacovigilance study of torsade de pointes

Conditions: Torsades de Pointe Caused by Drug

Summary: many cardiac and non-cardiac drugs are associated with tdp that may constitute a significant problem because of sudden cardiac death. this study aims to present a comprehensive overview and disproportionality analysis of tdp cases reported to the food and drug administration adverse event reporting system (faers) in order to identify new signals of tdp.

drug-induced torsade de pointes (tdp) is a serious but an overlooked adverse drug reaction because a wide range of marketed drugs associated with tdp are commonly prescribed in routine practice. owing to the heightened concern of a vast number of drug-tdp associations including newly approved drugs, the investigators, therefore, aims to investigate drug-tdp associations by performing disproportionality analysis in order to identify new signals of tdp utilizing the individual case reports of tdp in the faers database.

Eligibility criteria:
inclusion criteria: * tdp cases reported in the faers database till 31/03/2019 * adverse event reported was including the meddra term: torsade de pointes exclusion criteria: * drugs with less than 10 tdp reports
safety and efficacy study of umbilical cord/placenta-derived mesenchymal stem cells to treat ankylosing spondylitis (as)

Conditions: Ankylosing Spondylitis

Summary: the purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (mscs) derived from human umbilical cord/placenta at a dose of 1.0e+6 msc/kg in subject for the therapy of ankylosing spondylitis (as)

ankylosing spondylitis (as) is a chronic, progressive inflammatory rheumatic disease involving primarily the sacroiliac joints and the axial skeleton. the main clinical features are back pain and progressive stiffness of the spine. oligoarthritis of the hips and shoulders, enthesopathy, and anterior uveitis are common, and involvement of the heart and lungs is rare. the current understanding of the pathogenesis of this disorder is limited.it mainly about to hereditary susceptibility (eg hla-b27),infection and autoimmunity. although traditional drugs, such as nonsteroidal antiinflammatory drugs (nsaids) disease-modifying antirheumatic drugs (dmards such as mtx,sasp or thalidomide) and steroids have been used in the treatment of as, however, many studies have indicated that the overall response to these drugs is not satisfied. addition, the severe side effects of these drugs have also been observed. the management of as patients therefore remains unsatisfactory and targeted therapies are needed. human mscs isolated from human umbilical cord/placenta have been shown to have immunoregulatory, immunosuppressive, stimulating hematopoiesis and tissue repairing properties. this study will evaluate the safety and effectiveness of msc transplantation in the as patients. this study will last 2 to 3 years. participants will be randomly assigned to receive either msc transplant +dmards therapy (experimental group) or dmards therapy (control group). patients will undergo msc transplant at the start of the study on day 0. after 3 months, patients will receive the second msc transplantation. after six and twelve months from the first transplantation, patients will be evaluated.

Eligibility criteria:
inclusion criteria: 1. patient age 18\~60 years old with plan to infuse mscs. 2. diagnosis of "definite as" (arthritis of the spine) as defined by the modified new york criteria 3. stable doses of sulfasalazine,methotrexate,thalidomide,hydroxychloroquine, low-dose corticosteroids, and nsaids are permitted 4. patients must have an ecog 0\~2. 5. no moderate or sever organ dysfunction: ejection fraction\>45%; creatinine \<176 umol/l. 6. no severe infection. 7. each patient must sign written informed consent. exclusion criteria: 1. other serious concomitant diseases (uncontrolled/severe kidney, liver, haematological, gastrointestinal, endocrine, cardiovascular, pulmonary, neurological or cerebral disease) 2. psychiatric condition that would limit informed consent. 3. hiv, hepatitis b or c, tuberculosis, other infections 4. positive pregnancy test or lactation 5. patient has enrolled another clinical trial study within last 4 weeks. 6. contraindications to msc

Keywords: ankylosing spondylitis umbilical cord/placenta-derived msc transplantation
clinical study of 68ga labeled her2 affibody analogues

Conditions: HER2-positive Breast Cancer and Gastric Cancer

Summary: the purpose of this study is to assess the dosimetric properties of the positron emission tomography (pet) imaging probe 68ga labeled her2 affibody analogues and preliminarily evaluate its diagnosis value in patients with breast or gastric tumors.

6 healthy volunteers with whole-body pet/ct scans at 0-1.0, 2.0, 3.0 and 4.0 hours after tracer injection (mean dose, 4.93 ± 0.10 mci) will be performed. during the imaging period, 1 ml blood samples will be obtained specifically at 1, 3, 5, 10, 30,60, 90, 120, 150, 180 and 240 minutes after the injection, for time-activity curve calculations. the estimated radiation doses will be calculated by using olinda/exm software. 50 patients with breast or gastric tumors will be enrolled for the clinical study, they will be performed with both 68ga-her2 affibody pet/ct and18f-fdg pet/ct scans before surgery. the preoperative images are compared and correlated with the pathologically report. next, the expression of her2 will be determined by immunohistochemical staining of the resected brain tumor tissues.

Eligibility criteria:
inclusion criteria: * patients with breast or gastric cancers: diagnosed by mr and ready for surgery exclusion criteria: * refuse or cannot endure surgery pregnant women
evaluating acupuncture relationship with the catecholaminergic pathway

Conditions: Low Back Pain

Summary: activation of the sympathetic nervous system attenuates inflammation via catecholamines, recent advances in electroacupuncture allow activating critical neuronal networks with the release of catecholamines the aim of this research was to evaluate de effect of electroacupuncture in the activation of sympathetic nervous system and the control of low back pain in athletes

activation of the sympathetic nervous system attenuates inflammation via activation of β2-adrenoreceptors by catecholamines, electrical stimulation of vagus nerve limits the inflammatory response in several animal models of inflammatory diseases, in addition, voluntary activation of the sympathetic nervous system by meditation, training or breathing techniques limits production of proinflammatory cytokines in vivo during experimental endotoxemia in healthy human volunteers. currently there are therapies that effectively antagonize proinflammatory cytokines and control pain, as non-steroidal anti-inflammatory drugs and opioid analgesics, but had serious side effects if used chronically. therefore, alternative therapies as electroacupuncture, which may limit inflammatory cytokine production more physiologically, are warranted. the aim of this study was to evaluate de effect of electroacupuncture used for attenuation of low back pain in the activation of sympathetic nervous system and leukocyte inflammatory potential.

Eligibility criteria:
inclusion criteria: (controls) * healthy * non smokers * athletes (cases) * acute low back pain (less than 1 month) * athletes * non smokers exclusion criteria: * sciatic pain * smokers * chronic low back pain
understanding the phenomena of aging and rupture of breast implants

Conditions: Aging of Breast Implants

Summary: breast implants, like all implantable medical devices, are subject to wear and tear as they age in the body. in addition to this wear and tear, they are subject to external trauma, whether accidental during daily life, during insertion or during mammography. the kinetics and mechanisms of aging are poorly studied and the phenomenon of implant rupture is not elucidated. however, studies of older generation implants have shown that implant rupture is correlated with the duration of implantation.


Eligibility criteria:
inclusion criteria: * female adult (≥18 years old) * operated on at the hus for a change of breast prosthesis, aesthetic or reconstruction, between 2022 and 2024 * having not expressed, after information, her opposition to participate in this research. exclusion criteria: * women who have expressed their opposition to participating in the study * ruptured prosthesis, associated with a lagc-aim, excessive perspiration * interfering treatments and associated diseases, history

Keywords: breast prosthesis implantation aging of breast implants rupture of breast implants
post-marketing study using prolieve® for the treatment of benign prostatic hyperplasia (bph)

Conditions: Benign Prostate Hyperplasia

Summary: the primary objective of the post-marketing study is to collect safety and effectiveness data for 5 years on subjects treated with prolieve®. the collection of 5-year safety information will be used to evaluate the occurrence of any long-term side effects from the treatment. the collection of long-term effectiveness data on subjects treated with prolieve® will provide information on the long-term effects of treatment and time to re- treatment (any treatment initiated for bph since prolieve'" treatment, including a second treatment with prolieve").


Eligibility criteria:
inclusion criteria: * diagnosed with symptomatic bph. * peak urine flow rate \ 125ml. * aua symptom score value ≥9(9). * signed informed consent. exclusion criteria: * subjects whose pain response has been significantly decreased by any means (because the subject's ability to detect pain is a treatment safety mechanism). * subject with a history of any illness or surgery that might confound the results of the study " or impede the successful completion of trial" * subject with a history of any illness for which the prolieve® treatment may pose additional risk to the subject. * subject with the confirmed or suspected malignancy of the prostate * subject with the confirmed or suspected bladder cancer * psa \>10 ng/ml * subject with previous treatment to the prostate (e.g., surgery, balloon dilation, stents, laser, tuna, or indigo prostatectomy) and/or non-metallic urogenital implants (e.g., penile prostheses, artificial urinary sphincters) * subject with prostate weighing \ 80g. * subject with previous pelvic irradiation or radial pelvic surgery * subject having large, obstructive middle lobe * previous rectal surgery (other than hemorrhoidectomy) or history of rectal disease. * subject with urethral stricture and/or bladder stones * active urinary tract infection. * subject with neurogenic bladder and/or sphincter abnormalities due to parkinson's, multiple sclerosis, cerebrovascular accident (cva), diabetes, or other disease process. * residual bladder volume \>250 ml measured by ultrasound. * compromised renal function (i.e., serum creatinine levels above 1.8 mg/dl). * cardiac pacemaker or metallic implants or staples, etc. in the pelvic or femoral area. * concomitant medicating of the following: 1. bladder antispasmodics (ditropan or detrol) within one week of treatment, unless there is documented evidence that the subject has been on the same drug dose for at least three months with a stable voiding pattern. the drug dose will not be altered or discontinued for the entrance into or throughout the study. 2. 5-alpha reductase inhibitors and gonadotropin releasing hormonal analog. 3. alpha blockers, antidepressants, androgens, within one week of treatment. * subject interested in future fertility/fathering children. * subject with full urinary retention. * subject with bleeding disorder or liver dysfunction associated with a bleeding disorder. * subject with prostatic urethra length of \ 5.5 cm.

Keywords: bph
high dose interval vitamin d supplementation in patients with ibd receiving remicade

Conditions: IBD; Ulcerative Colitis; Crohn Disease

Summary: the goal of this study will be to assess the safety and efficacy of high-dose interval vitamin d3 therapy in children and young adults with inflammatory bowel disease being treated with serial remicade infusions.

study subjects will receiving 50,000 units of vitamin d3 if they receive remicade infusions every 4-6 weeks. study subjects will receiving 100,000 units of vitamin d3 if they receive remicade infusions every 6-8 weeks.

Eligibility criteria:
inclusion criteria: * existing diagnosis of ibd * age 0-25 years * measured serum level of 25-oh vitamin d of 15-29 ng/ml in the last 8 weeks and no changes in vitamin d supplementation in the interim exclusion criteria: * pregnant women * history of underlying kidney disease * history of granulomatous disease * inability to take oral vitamin d * history of hypercalcemia or hypercalciuria * currently taking an anti-epileptic medication * history of pre-existing liver disease (excluding primary sclerosing cholangitis, non-alcoholic fatty liver disease, or steatohepatitis)

Keywords: ibd
the efficacy of g-csf against adhesion reformation after hysteroscopic adhesiolysis

Conditions: Intrauterine Adhesion

Summary: the purpose of this study is to investigate the efficacy of granulocyte colony stimulating factor(g-csf) on decreasing adhesion reformation and improving fertility outcomes after hysteroscopic adhesiolysis in patients with moderate to severe intrauterine adhesions.

after hysteroscopic adhesiolysis, patients with moderate to severe intrauterine adhesions will be allocated into 2 groups randomly, with cook ballon and estrogen and progesterone sequential therapy given to prevent adhesion routinely. 7 day later, g-csf or normal saline will be injected into the uterine cavity by tom catheter after removing the balloon respectively. a second hysteroscopic examination will be performed in 2 months to check up the adhesion reformation. in addition, the endometrial thickness after surgery and fertility outcome will be followed up.

Eligibility criteria:
inclusion criteria: * moderate and severe intrauterine adhesion patients(afs score ≥5) * age 18-40 * first time receiving hysteroscopic adhesiolysis * provided cook balloon as adjuvant adhesion prevention treatment * accepting randomized trial exclusion criteria: * mild adhesion patients * uterine shape can't be restored in the end of surgery * abnormal chromosome phenotype * systemic disease * no fertility desire * contradiction of g-csf injection.

Keywords: g-csf adhesion reformation asherman syndrome
autism registry for french guiana

Conditions: Autism Spectrum Disorder

Summary: the objective of the autism registry is to estimate the prevalence of autism in french guiana in the cohort of children aged 8 years. secondary objectives are to determine the prevalence of comorbidities, and to determine the theoretical and actual orientation of these children regarding care and education in a territory with significant structural deficits relative to mainland france. the outcomes of this registry will be to guide decision makers in their funding priorities to improve, screening, diagnosis, care and education for children on the autistic spectrum


Eligibility criteria:
inclusion criteria: * children aged 8 years with a diagnosis of autism spectrum disorder exclusion criteria: * refusal to participate
molecular genetic screening and identification of congenital arrhythmogenic diseases

Conditions: Long QT Syndrome; Hypertrophic Cardiomyopathy; Arrhythmogenic Right Ventricular Dysplasia

Summary: the aim of this study is the identification of familial congenital arrhythmogenic disorders and their clinical follow-up.

molecular genetic screening in patients with: * supraventricular * ventricular arrhythmia * syncopes of unknown origin and/or suspicion of an arrhythmogenic origin * family members of patients with sudden cardiac death and aborted sudden cardiac death examination of patients includes routine testing like electrocardiogram (ecg), sequential ecgs, exercise testing, invasive electrophysiological stimulation, cardiac magnetic resonance imaging, intravenous drug challenge for identification/exclusion of eg brugada syndrome. examples are patients with long qt syndrome, short qt syndrome, brugada syndrome, familial atrial fibrillation, wpw-syndrome, arrhythmias due to familial hypertrophic cardiomyopathy or arrhythmogenic right ventricular dysplasia. blood samples are taken for further molecular genetic screening.

Eligibility criteria:
inclusion criteria: * patients with a history of syncope, abnormal ecg and suspicion of an arrhythmogenic disease * patients with long qt syndrome * patients with short qt syndrome, shortened qt intervals, borderline shortened qt intervals * patients with brugada syndrome * patients with hypertrophic cardiomyopathy * patients with arrhythmogenic right ventricular dysplasia exclusion criteria: * inability to understand study protocol

Keywords: long qt syndrome hypertrophic cardiomyopathy arrhythmogenic right ventricular dysplasia short qt syndrome brugada syndrome
coenzyme q 10 and fertility outcome in women with clomiphene resistant pcos

Conditions: Coenzyme q10

Summary: the study evaluates the effect of coenzyme q 10 on ovulation and subsequent pregnancy in women with polycystic ovarian syndrome. half of the participants will receive coq10 and ovulation induction with clomiphene and other half would receive a placebo with clomiphene.


Eligibility criteria:
inclusion criteria: * diagnosis of polycystic ovarian syndrome pcos based on the revised 2003 consensus on diagnostic criteria and long-term health risks related to pcos (2003). * all women were previously treated with 100 mg of cc daily for 5 days per cycle, for two to three cycles with persistent anovulation or ovulate with very thin endometrium \<5 mm at the time of hcg administration exclusion criteria: * non-consenting. * known autoimmune disorders * prior treatment of endometriosis or surgery to reproductive tract * prior history of pelvic inflammatory disease * those with tubal factors and uterine factors as assessed on history and confirmed by normal hysterosalpingogram. * thyroid disorder as assessed by history examination and tsh level * patients with raised fsh

Keywords: ovulation induction coenzyme q10 pregnancy rate